Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Core Viewpoint - Lipella Pharmaceuticals Inc. has been delisted from The Nasdaq Capital Market due to non-compliance with specific listing rules related to private placement transactions [2][3]. Group 1: Delisting Details - The delisting was triggered by Nasdaq's findings that certain private placement transactions from December 2024 to March 2025 violated Listing Rules 5100, 5635, and 5640 [2]. - The specific issue involved the issuance of Series C voting convertible preferred stock and warrants to the Company's placement agent, which was deemed non-compliant [2]. Group 2: Company Response - Lipella expressed disappointment over the delisting decision, emphasizing its efforts to obtain stockholder approval to address Nasdaq's concerns [3]. - The Company remains operationally sound and is continuing its strategic and clinical development plans, including advancing its lead product candidates LP-10 and LP-310 [4]. Group 3: Future Plans - Lipella is exploring other markets for relisting its common stock to ensure better liquidity and access for investors [5]. - The Company will continue to file periodic reports with the U.S. Securities and Exchange Commission and keep stockholders informed of material developments [5]. Group 4: Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, reformulating existing generic drugs for new applications [6]. - The Company completed its initial public offering in 2022 [6].